Iodine-131 MIBG uptake in metastatic medullary carcinoma of the thyroid. A patient treated with somatostatin.
A 47-year-old man with multiple endocrine neoplasia (MEN) type 2a syndrome in whom metaiodobenzylguanidine (MIBG) concentrated in lesions from metastatic medullary carcinoma of the thyroid is reported. A somatostatin analogue (Sandostatin SMS 201-995) alleviated the symptoms of flushing and diarrhea associated with the elevated calcitonin levels but it did not alter either the course of the disease or the MIBG images. A review of the literature is presented of the noncatecholamine secreting tumors associated with MIBG uptake. Similarities between this case and metastatic carcinoid syndrome are discussed.
D019797:3-Iodobenzylguanidine; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000378:metabolism / Q000556:secondary*; D006801:Humans; D007457:Iodine Radioisotopes; D007462:Iodobenzenes / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009377:Multiple Endocrine Neoplasia / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism; D015282:Octreotide; D011877:Radionuclide Imaging; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013125:Spinal Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism / Q000556:secondary*; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism
D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine; D013004:Somatostatin; D015282:Octreotide